Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Green light for new medicines in the EU

Written by | 13 Apr 2023

The European Medicines Agency (EMA) approved a total of 89 new medicines in 2022. Of these, 41 had a new active substance which had never been authorised in… read more.

Four new medicines approved by EMA

Written by | 4 Feb 2023

The European Medicines Agency (EMA) has approved four new medicines at its January meeting, getting 2023 off to a low-key start. The Agency’s key human medicines committee (CHMP)… read more.

EU green light for 12 new medicines – including 5 orphan drugs

Written by | 8 Oct 2022

The European Medicines Agency (EMA) has approved 12 new medicines at the September meeting of its key decision-making panel, the Committee on Human Medicinal Products (CHMP). The expert… read more.

CHMP recommends Opdivo for the adjuvant treatment of adults with muscle-invasive urothelial carcinoma – BMS

Written by | 6 Jul 2022

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) for the… read more.

EU gives green light for four new medicines

Written by | 1 May 2022

The European Medicine Agency’s key expert body – the Committee for Medicinal Products for Human Use (CHMP) – has recommended that four medicines be approved in the EU…. read more.

EMA approved 91 products in 2021

Written by | 12 Jan 2022

Thirteen new medicines were given the green light at the December meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). This brings to… read more.

EU green light for more than 50 new drugs in 2021

Written by | 6 Sep 2021

The European Medicines Agency (EMA), the EU’s drug regulator, has now approved a total of 52 new medicines for human use in the first seven months of the… read more.

Myovant Sciences receives positive CHMP opinion for Ryeqo (relugolix combination tablet) for the treatment of women with uterine fibroids

Written by | 27 May 2021

Myovant Sciences announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of Ryeqo (relugolix… read more.

CHMP recommends approval of Enspryng for neuromyelitis optica spectrum disorder – Roche

Written by | 2 May 2021

Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Enspryng (satralizumab) as the first subcutaneous treatment option… read more.

CHMP issues advice on the use of Celltrion’s regdanvimab (CT-P59) for COVID-19 patients in the European Union

Written by | 1 Apr 2021

Celltrion Group announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for the company’s anti-COVID-19 monoclonal antibody… read more.

GW Pharmaceuticals receives positive CHMP opinion for Epidyolex for use as treatment of seizures associated with tuberous sclerosis complex

Written by | 14 Mar 2021

GW Pharmaceuticals plc , a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for… read more.

EMA backs six new medicines

Written by | 14 Mar 2021

Article written by Gary Finnegan. The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six medicines for approval at its February 2021 meeting:

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.